New study aims to help vulnerable canadians quit smoking with nicotine spray and cytisine

NCT ID NCT03249428

ENROLLING_BY_INVITATION Disease control Sponsor: Ottawa Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two approaches to help people who are homeless or at risk of homelessness quit smoking: cytisine (a plant-based pill) versus nicotine replacement therapy (like mouth spray, patches, or gum). Both groups also get counseling. The goal is to see which strategy works better and improves quality of life. The trial involves 200 participants in Ottawa and Toronto.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cytisine and nicotine replacement therapy (mouth spray, patches, gum, lozenges, inhalers)
What this could lead to: If successful, this could provide an effective, low-cost way to help disadvantaged populations quit smoking, reducing tobacco-related deaths and improving quality of life.
What could go wrong: This is a small, early-stage trial (200 participants) with no blinding, so results may not be generalizable. Quit rates may be low, and participants may relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nicotine dependence psychiatric disorder substance abuse substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD ASTHMA MENTAL ILLNESS SUBSTANCE USE TOBACCO DEPENDENCE

Contacts and locations

Locations

The Bridge Engagement Centre

Ottawa, Ontario, K1K 4B7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.